A major pharmaceutical partnership was announced Friday as Pfizer and Chinese biotechnology company Innovent Biologics revealed a comprehensive licensing and collaboration agreement valued at up to $10.5 billion for developing 12 experimental cancer treatments.
The financial structure includes an immediate $650 million payment to Innovent, with an additional $9.85 billion possible through development, regulatory approval, and sales milestone achievements.
The collaboration focuses on a collection of antibody-drug conjugates featuring novel differentiated payloads and multi-specific antibodies, incorporating eight early-stage assets originated by Innovent and four discovery programs proposed by Pfizer.
According to the agreement terms, Innovent will spearhead the development of all 12 programs through Phase 1 clinical testing, after which Pfizer will assume responsibility for worldwide development activities.
The partnership operates through three distinct tiers. Four programs will involve joint development and commercialization, with shared profits in the United States and Europe while Innovent maintains rights in Greater China.
For an additional four programs, Pfizer obtains exclusive licensing rights outside Greater China, while securing exclusive global licensing and assuming all worldwide development expenses for the final four programs.
Innovent confirmed in an exchange filing that the company, along with its wholly-owned subsidiaries Innovent Biologics (Suzhou) and Fortvita Biologics (USA), has entered into this agreement with Pfizer.
